Qiagen N.V.
HealthcareNYSE:QGEN · New York Stock Exchange
-$0.30 today
Vol 1.70M · Avg 2.30M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.1B of revenue converted into $402.2M of net income for the selected period. Gross margin is 61.6% and net margin is 19.1%, showing how much revenue survives after costs and taxes. EPS is $1.89, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1B +5.7% | $2.0B +0.7% | $2.0B -8.2% | $2.1B -4.9% | $2.3B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $798.5M -21.0% | $1.0B +38.2% | $731.6M -3.3% | $757.0M -5.5% | $800.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.3B +33.5% | $967.4M -21.6% | $1.2B -10.9% | $1.4B -4.6% | $1.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.8% +12.9pp | 48.9% -13.9pp | 62.8% -1.9pp | 64.7% +0.2pp | 64.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $187.5M -3.1% | $193.5M -2.5% | $198.5M +4.6% | $189.9M -0.1% | $190.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $583.7M +3.4% | $564.4M -2.6% | $579.2M -4.1% | $603.9M +3.3% | $584.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $771.2M -11.3% | $869.6M +5.6% | $823.8M -3.4% | $853.1M +3.9% | $820.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $193.7M -4.7% | $203.3M -1.0% | $205.3M -1.5% | $208.4M -3.0% | $214.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $717.3M +94.8% | $368.3M -46.5% | $688.6M -11.7% | $779.4M -12.9% | $895.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 34.3% +15.7pp | 18.6% -16.4pp | 35.0% -1.4pp | 36.4% -3.4pp | 39.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $520.3M +432.5% | $97.7M -76.2% | $409.9M -22.9% | $531.5M -15.7% | $630.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 24.9% +20.0pp | 4.9% -15.9pp | 20.9% -4.0pp | 24.8% -3.2pp | 28.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $64.3M -5.4% | $68.0M -13.9% | $79.0M +141.1% | $32.8M +242.8% | $9.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $33.3M -24.1% | $43.8M -17.9% | $53.4M -8.5% | $58.4M +7.1% | $54.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$30.0M -228.2% | $23.4M +17.9% | $19.9M +205.4% | -$18.9M -343.6% | -$4.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $490.3M +304.7% | $121.1M -71.8% | $429.8M -16.2% | $512.6M -18.1% | $625.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 23.5% +17.3pp | 6.1% -15.7pp | 21.9% -2.1pp | 23.9% -3.9pp | 27.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $65.4M +74.1% | $37.6M -57.6% | $88.5M -1.0% | $89.4M -21.1% | $113.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $424.9M +408.3% | $83.6M -75.5% | $341.3M -19.4% | $423.2M -17.4% | $512.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 20.3% +16.1pp | 4.2% -13.1pp | 17.4% -2.4pp | 19.8% -3.0pp | 22.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +423.1% | $0 -76.6% | $2 -19.7% | $2 -17.5% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +436.8% | $0 -77.0% | $2 -19.5% | $2 -17.0% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $207.9M -3.9% | $216.4M -0.5% | $217.5M -1.5% | $220.7M -0.2% | $221.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $207.9M -4.8% | $218.5M +0.5% | $217.5M -2.6% | $223.2M -0.8% | $225.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Exelixis, Inc.
NASDAQ:EXEL
$13.38B
Align Technology, Inc.
NASDAQ:ALGN
$12.51B
ICON Public Limited Company
NASDAQ:ICLR
$11.20B
Revvity, Inc.
NYSE:RVTY
$11.12B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.84B
Baxter International Inc.
NYSE:BAX
$10.72B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.06B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.72B
Bio-Techne Corporation
NASDAQ:TECH
$8.48B
Hims & Hers Health, Inc.
NYSE:HIMS
$5.97B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does QGEN generate?
Qiagen N.V. (QGEN) reported $2.09B of revenue in fiscal 2025.
Is QGEN profitable?
Qiagen N.V. (QGEN) reported $424.88M of net income, with a net margin of 20.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.